InvestorQ : What does the failure of Glenmark’s Umifenovir mean for the company?
Khushi Patel made post

What does the failure of Glenmark’s Umifenovir mean for the company?

Answer
user profile image
Dhwani Mehta answered.
2 weeks ago


I am not sure if you can really call it a failure as it is still an evolving areas. On Friday, Glenmark had stated that the addition of Umifenovir did not demonstrate any additional benefit over Favipiravir in moderate Covid-19 patients.

This has nothing to with Favipiravir but only with the efficacy of adding Umifenovir. The results only show that the by adding Umifenovir there was no additional therapeutic benefit seen in the use of Favipiravir. That is all that the company has said.

However, the company has also added that the Favipiravir alone remains the effective choice for mild to moderate COVID-19 infection. This must not be mixed up with Remdesivir, which is used in more acute forms of COVID-19 affliction.

It may be recollected that Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings. It was approved as an anti-flu drug in Japan in 2014 and the DCGI has approved it in India for mild COVID. On the other hand, Umifenovir is licensed as a treatment for certain types of flu afflictions in Russia and China.